UPDATE: Piper Jaffray Maintains Overweight On Rockwell Medical, Lowers Target To $6 Notes 'As Feared, Triferic IV Not TDAPA Eligible; Lowering Estimates Meaningfully'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/12/2019 17:22